Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema

NCT04600362 | Active Not Recruiting Phase 2

• 1 other identifier: SGZ-2018-12012
• Study Type: interventional
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

Nummular eczema (NE) is an idiopathic chronic inflammatory skin disease that occurs throughout all life periods. Diagnosis is made primarily clinically in correlation with histological findings. Treatment of NE is difficult. Standard treatment consists of the use of emollients, topical as well as systemic corticosteroids and phototherapy. Nevertheless, remission is hard to achieve and relapse occurs often. Patients usually suffer from severe pruritus and reduced quality of life. Therefore, new therapeutic strategies are urgently needed. Dupilumab (Dupixent®), a monoclonal antibody inhibiting the IL-4 and IL-13 pathway by targeting the IL-4-receptor, has been approved for the treatment of moderate-to-severe atopic dermatitis (AD). Since there is an overlap between AD and NE with both being caused by impaired epidermal barrier, broad immune-mediated inflammation and microbial skin colonization, using Dupilumab in NE seems to be promising.

Conditions

Nummular Eczema

Keywords

Nummular Eczema; Dermatitis; Skin Diseases; Dupilumab; Anti-Inflammatory-Sgents

Outcome Measures

Primary Outcomes (1)

• EASI

  The primary endpoint is the percent change in Eczema Area and Severity Index (EASI) score.

  From baseline to week 16.

Secondary Outcomes (10)

• PGA

  at week 16 as compared to week 0

• PGA

  at Week 16.

• EASI

  From baseline to week 16

• TEWL

  From baseline to week 16

• histological improvement

  From baseline to week 16

Study Arms (2)

Dupilumab

EXPERIMENTAL

Patients randomized to this arm will receive two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by single 300 mg injection of Dupilumab every 2 weeks (q2w) from week 2 to week 16.

Drug: Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

Placebo

PLACEBO COMPARATOR

Patients randomized to this arm will receive identically matching doses of placebo. Two subcutaneous injections of placebo as a loading dose (to mimic the experimental Dupilumab arm) on Day 1 followed by a single injection q2w from Week 2 to Week 16.

Drug: Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

Interventions

Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] DRUG

Subcutaneous

Dupilumab; Placebo

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Clinically confirmed diagnosis of NE.
• Biopsy-proven, meaning histology consistent with eczema (including PAS-staining).
• EASI score ≥ 10.
• PGA ≥ 3 on a 5 point scale.
• Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial.
• Female participants who are not capable of bearing children or who use a method of contraception that is medically approved by the health authority of the respective country at screening. Effective contraception (CTFG guideline) for women of childbearing potential should be used throughout the study, including during the follow-up period or at least 120 days after last dose, whichever is longer (elapse of 4-5 half-lives). The event of pregnancy, Dupilumab should be immediately discontinued.
• History of continuous use of at least mid-potency topical steroids for the last 8 weeks.
• Age 18-85 years of age, body weight ≥ 40 kg and ≤ 160 kg.
• Signed informed consent from patient.

You may not qualify if:

• Permanent severe diseases, especially those affecting the immune system.
• Pregnancy or breast feeding.
• Active chronic or acute infection requiring systemic treatment within 2 weeks before the baseline visit, independent from of the cuntaneous dysbiosis found in NE.
• Treatment with an investigational drug within 8 weeks before the baseline visit.
• Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.
• Diagnosed active endoparasitic infections or at high risk of these infections.
• Evidence of severe renal dysfunction 8.Evidence of significant hepatic disease 9.Patients who are considered potentially unreliable or where it is envisaged the patient may not consistently attend scheduled study visits. 10.Inability or unwillingness to undergo repeated venipuncture (e.g., because of poor tolerability or lack of access to veins).
• Inability or unwillingness to undergo repeated punch biopsies. 12.History of allergy to any component of the study medication. 13.Evidence of acute contact dermatitis at screening. 14.Evidence of Zink deficiency defined as Zink level \< 20 µg/dL in serum. 15.History of important side effects of medium potency topical corticosteroids (eg, intolerance to treatment, hypersensitivity reactions\*, significant skin atrophy, systemic effects), as assessed by the investigator or patient's treating physician.
• \. ≥30% of the total lesional surface located on areas of thin skin that cannot be safely treated with medium potency TCS (eg, face, neck, intertriginous areas, genital areas, areas of skin atrophy) at baseline.
• \. Planned or anticipated use of any prohibited medications and procedures during study treatment.
• \. Known history of human immunodeficiency virus (HIV) infection. 19. Established diagnosis of Hepatitis B viral infection at the time of screening.
• \. Established diagnosis of hepatitis C viral infection at the time of screening.
• \. History of past or current tuberculosis or other mycobacterial infection. 22. Presence of skin comorbidities that may interfere with study assessments. 23. Malignancy within 5 years of the screening visit excluding local cutaneous squamous cell 24. Severe concomitant illness(es) 25. Any other medical or psychological condition including relevant laboratory abnormalities at Screening 26. Planned major surgical procedure during the patient's participation in this study.

Sponsors & Collaborators

• Technical University of Munich: lead
• University Hospital Munich: collaborator

Study Sites (1)

Klinikum re. Isar Dermatology

München, Bavaria, 81675, Germany

Location

Related Publications (1)

• Bohner A, Jargosch M, Muller NS, Garzorz-Stark N, Pilz C, Lauffer F, Wang R, Roenneberg S, Zink A, Thomas J, Theis FJ, Biedermann T, Eyerich S, Eyerich K. The neglected twin: Nummular eczema is a variant of atopic dermatitis with codominant TH2/TH17 immune response. J Allergy Clin Immunol. 2023 Aug;152(2):408-419. doi: 10.1016/j.jaci.2023.04.009. Epub 2023 Apr 27.

  PMID: 37119871 DERIVED

MeSH Terms

Conditions

Dermatitis; Skin Diseases

Interventions

dupilumab

Condition Hierarchy (Ancestors)

Skin and Connective Tissue Diseases

Study Officials

• Thilo Biedermann, Prof.Dr.med.

  Klinikum re. Isar, Technische Universität München, Dermatologie

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: double-blind
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: This is an investigator-initiated, multi-center, prospective, randomized, double-blind, interventional phase II study.

Study Record Dates

• First Submitted: October 19, 2020
• First Posted: October 23, 2020
• Study Start: March 30, 2021
• Primary Completion: September 1, 2025
• Study Completion (Estimated): January 31, 2027
• Last Updated: September 23, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will share
• Shared Documents: CSR
• Time Frame: A year later according to LPLV
• Access Criteria: Publikation

Locations

DE (1)